Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generics Bulletin Originals

Set Alert for Originals
What's Next?

What’s Next? Five Things To Look Out For In December

In a busy final month of the year, key legal action will be heard in both the US and Europe, while the Medicines Patent Pool will hear from applicants for a milestone voluntary licensing agreement covering Novartis’ nilotinib.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In November

European litigation, potential US generic launches and new CEOs are among the headlines in November – amid the ninth annual Global Generics & Biosimilars Awards, in Frankfurt.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In October

A busy October will include planned biosimilar launches and key appointments for the off-patent sector.

Generic Drugs Biosimilars

What’s Next? Five Things To Look Out For In September

As the fourth quarter of the year nears, plenty is on the horizon for industry, with senior management shifts and a slate of high-value launches in the US and Europe.

Generic Drugs Biosimilars
See All
Interviews

Science-Based Thinking Promises Global Progress On Biosimilars

A science-based approach to biosimilars, exemplified by the latest statement from European regulators, makes further progress on biosimilars just a matter of time, according to Gillian Woollett, vice president and head of regulatory strategy and policy at Samsung Bioepis.

Biosimilars Regulation

Rani Therapeutics: ‘We’ve Tested A Dozen Molecules, All Of Them Have Worked’

In an exclusive interview with Generics Bulletin, Talat Imran, CEO of oral-dose biologics player Rani Therapeutics, talks adalimumab, partnering opportunities and financing, in the wake of kicking off pre-clinical development of its RT-111 proposed biosimilar to Janssen’s Stelara (ustekinumab) contained in its proprietary RaniPill Go ‘robotic’ capsule.

Biosimilars Value-Added Medicines

Humira LOE Is ‘Uncharted Territory’ As Fierce Competition Expected

Discussing the latest developments in the US biosimilars market, AmerisourceBergen’s senior director of biosimilar commercialization, Brian Biehn, talks about what we can expect from competition to Humira in 2023, how the first ophthalmology biosimilars are faring, and potential changes on the horizon at the FDA that could smooth the path to market for biosimilars sponsors.

Biosimilars Market Intelligence

Faster And Cheaper: Similis Bio Aims To Enhance Biosimilar Development

In the wake of Similis Bio’s first biosimilar partnership, the JSR Life Sciences unit’s head, John Gabrielson, talks to Generics Bulletin about the Similis Bio model and how the firm believes it can help bring biosimilars to market more rapidly and efficiently.

Biosimilars Deals
See All
Pricewatch UK

Aripiprazole Returns To Lead October Rises In UK

Having led the fastest-rising average trade prices in the UK in August, aripiprazole once again topped our table of Biggest Risers in October, based on the latest figures from market researcher WaveData – but this time it was the oral solution presentation of the product that saw a spike.

Market Intelligence Pricing Strategies

Prices Double For Multiple UK Generics In September

September brought triple-digit percentage increases in the average trade price of multiple UK generics, according to the latest figures from WaveData.

Market Intelligence Pricing Strategies

Aripiprazole Leads A Slew Of UK Price Rises In A Dynamic August

Aripiprazole led the steepest UK generic price rises in August 2022, a hugely dynamic month that saw treble-digit percentage price increases for a number of molecules, according to the latest figures from WaveData.

Market Intelligence Pricing Strategies

UK Alendronate Prices Explode In July

An average price rise of over 1,400% was seen for alendronate 70mg tablets in the UK last month, as average prices for a host of other generics more than doubled.

Market Intelligence Pricing Strategies
See All
UsernamePublicRestriction

Register